X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dishman Pharma Fact Sheet, Dishman Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dishman Pharma Fact Sheet   (DHPH)

Here is the latest financial fact sheet of Dishman Pharma. For more details, see the Dishman Pharma quarterly results and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

DISHMAN PHARMA Price History

Price Rs 301.1
Mkt Cap Rs m 48,588
Vol '000 460.5
P/E X 25.1
P/CF X 17.3
EPS (TTM) Rs 12.0
% ch % 2.9
No. of shares m 161.39
% ch week % 3.5
% ch 1-mth % -2.4
% ch 12-mth % 96.4
52 week H/L Rs 346.3/127.6
(As on May 29, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DISHMAN PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
DISHMAN PHARMA EQUITY SHARE DATA
High Rs107122107183374 
Low Rs35423983129 
Sales per share (Unadj.) Rs139.3157.7171.7196.9197.8 
Earnings per share (Unadj.) Rs7.012.413.514.821.2 
Diluted earnings per shareRs3.56.26.87.410.6 
Cash flow per share (Unadj.) Rs16.522.827.033.534.7 
Dividends per share (Unadj.) Rs1.201.201.202.002.00 
Adj. dividends per shareRs0.600.600.601.001.00 
Dividend yield (eoy) %1.71.51.61.50.8 
Book value per share (Unadj.) Rs115.3128.2146.4153.4179.9 
Adj. book value per shareRs57.764.173.276.789.9 
Shares outstanding (eoy) m80.6980.6980.6980.6980.69 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.50.50.40.71.3 
Avg P/E ratio x10.16.65.48.911.9 
P/CF ratio (eoy) x4.33.62.74.07.2 
Price / Book Value ratio x0.60.60.50.91.4 
Dividend payout %17.19.78.913.59.4 
Avg Mkt Cap Rs m5,7296,6175,90210,69120,306 
No. of employees `0001.01.10.90.90.8 
Total wages/salary Rs m2,9413,5094,1234,2325,355 
Avg. sales/employee Rs Th11,541.312,059.014,848.018,430.919,252.7 
Avg. wages/employee Rs Th3,019.63,326.24,419.44,909.66,459.5 
Avg. net profit/employee Rs Th582.8950.61,171.21,389.92,064.1 
DISHMAN PHARMA INCOME DATA
Net Sales Rs m11,24112,72213,85315,88715,961 
Other income Rs m129178249869265 
Total revenues Rs m11,37012,90014,10216,75716,226 
Gross profit Rs m2,2452,9013,3213,1284,103 
Depreciation Rs m7658381,0861,5071,091 
Interest Rs m729788921897944 
Profit before tax Rs m8791,4531,5641,5932,334 
Minority Interest Rs m00000 
Prior Period Items Rs m00001 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m312450471394624 
Profit after tax Rs m5681,0031,0931,1981,711 
Gross profit margin %20.022.824.019.725.7 
Effective tax rate %35.431.030.124.826.7 
Net profit margin %5.07.97.97.510.7 
DISHMAN PHARMA BALANCE SHEET DATA
Current assets Rs m6,2396,7338,24510,13511,018 
Current liabilities Rs m6,5477,1279,02811,0489,517 
Net working cap to sales %-2.7-3.1-5.7-5.79.4 
Current ratio x1.00.90.90.91.2 
Inventory Days Days8797112103110 
Debtors Days Days6121385035 
Net fixed assets Rs m14,39114,57915,71715,82716,304 
Share capital Rs m161161161161161 
"Free" reserves Rs m8,2259,05110,03111,16712,907 
Net worth Rs m9,30710,34511,81312,37814,516 
Long term debt Rs m5,1214,3364,1213,3024,189 
Total assets Rs m22,49022,91126,27728,08929,805 
Interest coverage x2.22.82.72.83.5 
Debt to equity ratio x0.60.40.30.30.3 
Sales to assets ratio x0.50.60.50.60.5 
Return on assets %5.87.87.77.58.9 
Return on equity %6.19.79.39.711.8 
Return on capital %11.115.315.615.917.5 
Exports to sales %30.328.327.822.624.8 
Imports to sales %7.24.76.35.63.7 
Exports (fob) Rs m3,4043,5953,8553,5983,956 
Imports (cif) Rs m806599869891596 
Fx inflow Rs m3,9744,2103,9664,5764,952 
Fx outflow Rs m905695954974697 
Net fx Rs m3,0693,5153,0113,6014,255 
DISHMAN PHARMA CASH FLOW
From Operations Rs m 1,536 1,651 3,445 2,937 2,786 
From Investments Rs m -1,040 -1,173 -2,568 -1,581 -1,529 
From Financial Activity Rs m -680 -502 -741 -1,420 -941 
Net Cashflow Rs m -185 -23 136 -64 316 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 61.4%
Foreign collaborators 0.0%
Indian inst/Mut Fund 3.7%
FIIs 12.7%
ADR/GDR 0.0%
Free float 22.1%
Shareholders 46,261
Pledged promoter(s) holding 35.8%
 

Company Information

REGD OFF Bhadr-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad - 380 009
E-MAIL tushar.shah@dishmangroup.com WEB www.dishmangroup.com
TELEPHONE (079) 2644 3053 FAX (079) 2642 0198
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Comp., LBS Marg, Mumbai-78
AUDITOR Deloitte Haskins & Sells
CHM: Janmejay R. Vyas (MD) COMP SEC: Tushar D. Shah YEAR OF INC: 1983 BSE CODE: 532526 FV (Rs): 2 DIV YIELD (%): 0.3

More Pharmaceuticals Company Fact Sheets:   INDOCO REMEDIES  FRESENIUS KABI ONCO.  PFIZER  ALEMBIC PHARMA  TORRENT PHARMA  

Compare DISHMAN PHARMA With:   INDOCO REMEDIES  FRESENIUS KABI ONCO.  PFIZER  ALEMBIC PHARMA  TORRENT PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Higher; Automobile & PSU Stocks Rise(Closing)

Indian share markets continued to trade well above the dotted line in the afternoon session amid firm international markets.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - TEVA PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS